News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
SoCal's Neurocrine Biosciences (NBIX) Flunks Phase II Tourette Syndrome Study 1/18/2017
Kura Oncology Doses First Patient In Phase II Study Of Tipifarnib In Chronic Myelomonocytic Leukemia 1/17/2017
Concert Pharmaceuticals, Inc. (CNCE) Release: Company Provides Further Details On CTP-656 Development In U.S. And Europe 1/17/2017
Protagonist (PTGX) Release: Pharma Initiates Phase 2b Study Of Oral Drug Candidate PTG-100 In Ulcerative Colitis 1/17/2017
BioLineRx Release: Pharma Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA For Pancreatic Cancer 1/17/2017
Agenus (AGEN) Release: Company Announces Collaboration With The NCI To Evaluate The Combination Of Pembrolizumab (Keytruda, Merck & Co. (MRK)) With Prophage (Agenus Inc.) Autologous Vaccine 1/17/2017
Psyadon Release: Company Announces Positive Results From Phase IIb Clinical Study Of Ecopipam For The Treatment Of Tourette’s Syndrome In Children 1/17/2017
Corbus (CRBP) Release: Pharma Receives Orphan Designation For JBT-101 For The Treatment Of Systemic Sclerosis In The European Union 1/17/2017
AiCuris Release: Pharma Announces Publication Of Phase 2 Clinical Trial Results Of Investigational Anti-Herpes Simplex Virus Agent Pritelivir In JAMA 1/17/2017
JPM17: Why the Key to Gene Therapy Could be in an Old Bay Area Warehouse 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Study Of Sulfatinib In Second-Line Biliary Tract Cancer In China 1/16/2017
Sunovion Release: Biopharma Announces Pivotal Study Results For Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms In Children Compared To Placebo 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Combination Study Of Fruquintinib With Iressa (Gefitinib) In First-Line Non-Small Cell Lung Cancer 1/16/2017
Tocagen Release: Company Expands Toca 5, Phase II/III Clinical Trial For Recurrent Brain Cancer, To South Korea 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Sulfatinib Phase II Study In 2nd Line BTC In China 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Fruquintinib Combination Study In 1st-Line NSCLC 1/16/2017
Sunovion Release: Massachusetts Biotech Touts Binge Eating and ADHD Mid-Stage Trials Data 1/13/2017
JPM17: CureVac Release: Biotech's mRNA Program Fails Phase II Test, Putting Spotlight on Other Biotechs Like Moderna 1/12/2017
Shionogi Release: Pharma Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial 1/12/2017
Delcath Systems (DCTH) Release: Company Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort 1/12/2017
MorphoSys AG Release: Company Partner To Start Phase 2 Trial With Bimagrumab In Obese Patients With Type 2 Diabetes 1/12/2017
BioPharmX Release: Pharma Data Suggest Anti-Inflammatory Activity Of BPX-01 Topical Minocycline Gel 1/12/2017
JPM17: How Celgene (CELG) Wowed Yet Again 1/11/2017
Sangamo (SGMO) Release: Pharma Receives Orphan Drug Designation From The FDA For SB-318 Genome Editing Treatment For MPS I 1/11/2017
Vtesse Announces Dosing Of First Patient In Australia In Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 1/11/2017
CytoDyn (CYDY) Release: Biotech Files For Breakthrough Therapy Designation With The FDA For PRO 140 In HIV Therapy 1/11/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Sobi Release: First Patient Randomized In A Phase II Study Evaluating The Safety And Efficacy Of Anakinra In The Treatment Of Acute Gout 1/11/2017
Visterra, Inc. Release: Pharma Doses First Patient In Phase 2a Trial For VIS410, Its Monoclonal Antibody In Development For The Treatment Of Hospitalized Patients With Influenza A 1/11/2017
Finding a Complementary Secondary Endpoint in Lupus Clinical Trials 1/10/2017
G1 Therapeutics Release: Biotech Initiates Three Drug Development Programs In Breast Cancer 1/10/2017
TapImmune (TPIV) Release: Pharma Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients 1/10/2017
Sangamo (SGMO) Release: Company Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering 1/10/2017
Debiopharm Release: Biopharma Announces Positive Phase 2 Clinical Trial With Debio 1450 In ABSSSI Patients 1/10/2017
The Jackson Laboratory Release: Mark Adams Joins Company As Director, Microbial Genomic Services 1/10/2017
ThromboGenics NV (TBGNF) Release: Pharma Enrolls First Patients In Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) For Diabetic Macular Edema (DME) 1/10/2017
Galmed Pharmaceuticals Completes Patient Recruitment For ARREST Phase IIb NASH Study 1/9/2017
Can-Fite BioPharma (CFBI) Receives IRB Approval To Commence Patient Enrollment In Phase II NAFLD/NASH Trial In Q1 2017 1/9/2017
Menlo Therapeutics Starts Enrollment In Two Phase 2 Studies For Pruritus Associated With Atopic Dermatitis And Pruritus Following Burn Injury 1/9/2017
Probiodrug AG Announces Completion Of Recruitment For The SAPHIR Phase 2a Study Of Glutaminyl Cyclase Inhibitor PQ912 In Early Alzheimer's Disease Patients 1/9/2017
PTC Therapeutics (PTCT) Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna And Advance Its Innovative Pipeline 1/9/2017
The Medicines Company (MDCO) Announces Positive Top-Line Results From Day 180 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of Inclisiran (Formerly, PCSK9si) 1/9/2017
Aridis Pharma Reports Positive Clinical Data From Phase 1/2a Study Of Human Monoclonal Antibody AR-301 For Treating Pneumonia 1/6/2017
Genprex Announces Positive Interim Data From Phase II Clinical Trial Of Oncoprex For Late Stage Non-Small Cell Lung Cancer 1/6/2017
Neurocrine Biosciences (NBIX) Provides Update On FDA Advisory Committee For INGREZZA (Valbenazine) For The Treatment Of Tardive Dyskinesia 1/6/2017
PTC Therapeutics (PTCT) Release: RG7916 Granted Orphan Drug Designation In The U.S. For The Treatment Of Spinal Muscular Atrophy 1/6/2017
Mirati Therapeutics  (MRTX) Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs 1/6/2017
DS Biopharma Announces That Recruitment Has Begun In Two Separate Phase 2b Atopic Dermatitis Studies With Lead Compound DS107 As Well As The Successful Completion Of A Phase 1 Trial For Follow On Compound DS109 1/6/2017
TLC Biopharmaceuticals, Inc. Reports Results Of Phase 1/2 Clinical Trial Of TLC599 For Sustained Pain Relief In The Treatment Of Osteoarthritis Of The Knee 1/6/2017
Puma Biotech (PBYI) Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients 1/6/2017
Viamet Reports Positive Results From RENOVATE Phase 2b Trial Of Oral VT-1161 In Onychomycosis 1/6/2017
Viamet Reports Positive Results From REVIVE Phase 2b Trial Of Oral VT-1161 In Recurrent Vulvovaginal Candidiasis 1/6/2017
Janssen Biotech (JNJ) Enters Immunotherapy Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Daratumumab (DARZALEX) In Combination With Nivolumab (OPDIVO) 1/5/2017
Halozyme (HALO) Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints 1/5/2017
Synthetic Biologics (SYN)' SYN-004 (Ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection (CDI) 1/5/2017
Gemphire Provides Clinical Update 1/5/2017
Cascadian Therapeutics (ONTY) Announces 2017 Outlook And Recent Drug Portfolio Progress 1/5/2017
Soligenix (SNGX) Receives Positive Scientific Advice From The EMA For SGX942 In The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 1/5/2017
Rigel (RIGL) Provides Business Updates And Preliminary Data In IgA Nephropathy 1/5/2017
Xigen S.A.’s Brimapitide, An Innovative JNK Inhibitor, Delivers Positive Phase II Results In Inflammatory Eye Disease 1/5/2017
Heron (HRTX) Announces Positive Topline Results From Phase 2 Clinical Trial Of HTX-011 In Abdominoplasty 1/5/2017
Heron (HRTX) Establishes Synergy Of Bupivacaine And Meloxicam With HTX-011 For Prevention Of Post-Operative Pain In Phase 2 Clinical Studies 1/5/2017
Genocea (GNCA) Announces Positive 6-Month Results From GEN-003 Phase 2b Clinical Trial 1/5/2017
Ritter Pharmaceuticals, Inc. Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published In PNAS 1/4/2017
Lycera Announces Initiation Of Phase 1/2a Study ARGON Of Immuno-Oncology Candidate LYC-55716 In Patients With Advanced Solid Tumors 1/4/2017
Ionis Pharma (IONS) Reports Positive Data From Phase 2 Study Of IONIS-GCGR Rx In Patients With Type 2 Diabetes 1/4/2017
US FDA Grants Orphan Drug Designation To YiSheng BioPharma's PIKA Rabies Vaccine 1/4/2017
Senhwa Biosciences CX-4945 Granted Orphan Drug Designation By The US FDA In Cholangiocarcinoma 1/4/2017
BioPharmX Completes Enrollment Of BPX-01 Phase 2b OPAL Clinical Trial For Acne Vulgaris 1/4/2017
NeuroRx Announces FDA IND Clearance For NRX-101 Phase 2b/3 Study And Publication Of Promising Biomarker Data 1/4/2017
Ogeda Announces Positive Data From Phase IIa Trial Of Fezolinetant (ESN364) In The Treatment Of Menopausal Hot Flashes 1/4/2017
Karolinska Development AB Portfolio Company Dilafor Initiates Phase IIb Clinical Trial With Tafoxiparin In Women With Protracted Labor 1/4/2017
Therapix Announces Enrollment Of The First Patient For Clinical Trial At Yale For Treating Tourette's Syndrome Using Cannabinoid-Based Drug 1/4/2017
Cidara (CDTX) Completes Enrollment In Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical In Vulvovaginal Candidiasis 1/4/2017
Bird Rock Bio Receives Approval From ANVISA And CONEP To Initiate The First Phase 2 Study In Brazil Of Gerilimzumab For Rheumatoid Arthritis 1/3/2017
Eiger Biopharma Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH) 1/3/2017
Axsome (AXSM) Receives FDA Clearance Of IND For Phase II/III Trial Of AXS-05 In Alzheimer’s Disease Agitation 1/3/2017
Zynerba (ZYNE) Announces Initiation Of The FAB-C Exploratory Phase II Clinical Trial Of ZYN002 CBD Gel In Patients With Fragile X Syndrome 1/3/2017
Inventiva Announces Initiation Of Phase IIb Clinical Trial Of IVA337 For Treatment Of Non-Alcoholic Steatohepatitis (NASH) 1/3/2017
Marinus Pharma (MRNS) Receives FDA Orphan Drug Designation For Ganaxolone To Treat Fragile X Syndrome 1/3/2017
Incyte (INCY) Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi) In Graft-versus-Host Disease 1/3/2017
Newron Pharma (NWRN) Announces Encouraging Preliminary Results Of Its Phase IIa Study With Evenamide In Patients With Schizophrenia 1/3/2017
NewVac Reports Primary Endpoint Met In Phase II Clinical Trial Of Quisinostat In Combination With Paclitaxel And Carboplatin In Platinum-Resistant Ovarian Cancer 1/3/2017
4 Fatal Deaths in Seattle Genetics (SGEN)' Early-Stage Trials of AML Drug 12/30/2016
Corus Pharma, Inc. Reports Positive Topline Results Showing Clear Signal Of Clinical Benefit With Resunab (JBT-101) In Phase 2 Study In Systemic Sclerosis 12/29/2016
Humacyte Commences U.S. Phase II Arterial Bypass Clinical Trial 12/29/2016
Bavarian Nordic (BAVA.CO) Initiates Trial Of CV301 In Combination With Nivolumab In Patients With Lung Cancer 12/29/2016
Achillion (ACHN) Scores $15 Million Clinical Milestone From Janssen R&D for the Advancement of JNJ-4178 in Phase 2B 12/28/2016
ThromboGenics NV (TBGNF) Announces Protocol Amendment To Phase II CIRCLE Trial Evaluating THR-409 (Ocriplasmin) In Patients With Non-Proliferative Diabetic Retinopathy (NPDR) 12/28/2016
The 7 Worst Clinical Disasters of 2016 12/27/2016
After Fraud Probe, Alexion (ALXN) Reports Failed Soliris Trial 12/27/2016
Neothetics (NEOT) Initiates Phase 2 Proof Of Concept Trial For LIPO-202 For The Reduction Of Submental Subcutaneous Fat 12/27/2016
RespireRx (RSRX) Announces Positive Results From Phase 2B PACE Study Conducted By The University of Illinois Dronabinol Reduces Symptoms Of Obstructive Sleep Apnea 12/27/2016
Acceleron Pharma Announces First Patient Treated In Phase 2 Trial Of ACE-083 In Facioscapulohumeral Muscular Dystrophy 12/27/2016
Merrimack (MACK) Halts Phase II HERMIONE Study for Breast Cancer; Further Plans Revealed in January 12/22/2016
Ironwood (IRWD) And Allergan (AGN) Report Topline Phase IIb Data Supporting Further Investigation Of Linaclotide Colonic Release-2 (CR2) For Abdominal Pain In Non-Constipation Subtypes Of IBS 12/22/2016
Ironwood (IRWD) and Allergan (AGN) Report Topline Phase IIb Data Supporting Advancement Of Linaclotide Colonic Release-1 (CR1) In IBS-C 12/22/2016
NeuroDerm (NDRM) Announces Completion Of Patient Enrollment And Treatment In A Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 12/22/2016
Acadia (ACAD) Stock Screams Upward; Primary Endpoint Met in Phase II Study of Pimavanserin for Alzheimer’s 12/21/2016
AzurRx BioPharma (AZRX) Announces First Three Patients Included In Phase Ila Study With MS1819-SD For Endocrine Pancreatic Insufficiency 12/21/2016
Unexpected Clinical Results Cause Hansa Medical to Terminate Phase II With IdeS in Acquired TTP 12/21/2016
Gradalis Inc. Announces A Novel Combination Study Of Vigil EATC In Women With Advanced Ovarian Cancer 12/21/2016
Concert Pharmaceuticals, Inc. (CNCE) Initiates Phase 2 Clinical Trial Evaluating CTP-656 For The Treatment Of Cystic Fibrosis 12/21/2016
Revive Therapeutics Engages NYU School of Medicine For Cystinuria Phase 2 Study 12/21/2016
After Terminating BI-505 Phase II, BioInvent (BOVNF) Rebounds With Big Pharma Deal 12/21/2016
Opsona Announces Preliminary Results From Ongoing Study In Second Line Lower Risk Myelodysplastic Syndrome (MDS) Recently Presented At The 58th Annual Meeting Of American Society of Hematology 12/20/2016
Prima Biomed (PRR.AX) Receives UK Approval For AIPAC Study 12/20/2016
Astellas (ALPMY) Announces FDA Fast Track Designation For ASP0892, DNA Vaccine For Mitigation Of Severe Hypersensitivity Reactions Due To Peanut Allergy 12/20/2016
MeiraGTx Granted Orphan Drug Designation For Its A004 Gene Therapy Treatment For Retinitis Pigmentosa 12/20/2016
MRI Interventions (MRIC)’ ClearPoint Neuro Navigation System To Be Utilized In Medicenna’ Phase 2 MDNA55 Clinical Trial For The Treatment Of Recurrent Glioblastoma 12/20/2016
Genmab A/S (GEN.CO) Announces Submission Of Regulatory Application For Daratumumab In Relapsed/Refractory Multiple Myeloma In Japan And Updates Financial Guidance 12/20/2016
GenSight Biologics Reports Sustained Visual Acuity Gain At 78 Weeks In Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 12/20/2016
Eyenovia Announces Completion Of Second Phase II Study 12/20/2016
Cambridge Biotech Agios (AGIO) Terminates AG-519 for PK Deficiency, But Continues AG-348 For Same Condition 12/19/2016
RedHill Biopharma (RDHL) Announces First Patient Dosed In Phase Ib/II Study With YELIV For Multiple Myeloma 12/19/2016
BrainStorm Cell Reports On Successful End Of Phase 2 Meeting With FDA, Upcoming Phase 3 Trial And Planned Application For Hospital Exemption For NurOwn 12/19/2016
ContraVir Expands Phase 2a Trial Of Tenofovir Exalidex (Formerly CMX157) To Include Doses Above 100 Mg 12/19/2016
SAGE Therapeutics (SAGE) Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Mood Disorders 12/19/2016
BeyondSpring Pharmaceuticals Presents Encouraging Clinical Data For Lead Asset On Chemotherapy-Induced Neutropenia At 2016 American Society of Hematology Annual Meeting 12/19/2016
AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform For Treatment Of Hypertension 12/16/2016
OrthoTrophix Release: Significant Improvements In Knee Function After TPX-100 Administration In A Double-Blind, Placebo-Controlled Phase 2 Study Of Knee Osteoarthritis 12/16/2016
Allegro Ophthalmics LLC Completes Enrollment In DEL MAR Phase IIb, Stage 2 Clinical Trial Of Luminate For The Treatment Of Diabetic Macular Edema 12/15/2016
Boehringer Ingelheim Release: Nintedanib Granted Orphan Drug Designation For Treatment Of Mesothelioma 12/15/2016
Galapagos (GLPG.BR) Release: The Lancet Publishes FITZROY Study Results With Filgotinib In Crohn's 12/15/2016
Nanobiotix Reports Positive Phase I/II Preliminary Data On Feasibility And Safety Of NBTXR3 In Liver Cancers Trial 12/15/2016
Kiadis Pharma Announces Initiation Of A Phase I/II Clinical Trial With ATIR201 For Thalassemia 12/15/2016
Karuna And PureTech Announce Positive Results From Tolerability Proof-of-Concept Study Of KarXT, Being Developed For Schizophrenia And Alzheimer's 12/15/2016
vTv Therapeutics (VTVT) Announces Positive Topline Results From Phase 2 Study Of TTP273 In Type 2 Diabetes 12/15/2016
RespireRx (RSRX) Announces Data For CX1739 Clinical Study In Opioid Induced Respiratory Depression 12/15/2016
BrainStorm Cell Release: In-Depth Analyses Presented At International Symposium On ALS/MND Suggest Strong Biological Effect For NurOwn; Evidence Of Halting Of Disease Progression 12/14/2016
Genticel Reports Final Results Of GTL001 Phase II Trial In HPV16/18-Infected Women 12/14/2016
Ability Pharma Announces Orphan Drug Designation In The US For ABTL0812 In Pancreatic Cancer 12/14/2016
Positive Phase II In Eosinophilic Asthma For Pulmagen/Teijin Pharma 12/14/2016
BioPharm Executive: So Long 2016 (and Good Riddance?) 12/14/2016
Revance (RVNC) Announces Positive 24-Week Duration Of Effect In Interim Results From Phase 2 Cervical Dystonia Trial 12/13/2016
NovoCure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel May Be Safe As First-Line Treatment And May Improve Survival Of Patients With Recurrent Ovarian Cancer 12/13/2016
NovoCure Presents Second Cohort Of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel And Gemcitabine May Be Safe As First-Line Treatment And May Improve One-Year Survival Rate Of Patients With Advanced Pancreatic Cancer 12/13/2016
Centrexion Touts Success of Phase IIb Study for Knee Osteoarthritis Pain 12/13/2016
aTyr Pharma Reports Promising Signals Of Clinical Activity In Multiple Rare Genetically Distinct Myopathies With Resolaris In Exploratory Trials 12/13/2016
Arbutus Biopharma (ABUS) Provides Additional Data From The ARB-1467 Phase II Clinical Trial In HBV Patients 12/13/2016
Actinium (ATNM.OB) Announces Submission Of EU Orphan Designation Application For Actimab-A 12/13/2016
Zealand Pharma  (ZEAL.CO) Initiates Phase IIa Clinical Trial With Dasiglucagon In A Dual-Hormone Artificial Pancreas System From Beta Bionics 12/13/2016
Innocrin Presents Data From The Ongoing Phase II Trial Of Seviteronel In Estrogen Receptor-Positive Or Triple-Negative Breast Cancer (CLARITY-01) At The San Antonio Breast Cancer Symposium 12/13/2016
Aurinia (ISA.TO) Confirms Receipt Of FDA End of Phase II Meeting Minutes 12/13/2016
MorphoSys AG Starts Phase 2 Trial Of MOR208 In Combination With Idelalisib In Patients With Relapsed Or Refractory CLL Or SLL Previously Treated With A BTK Inhibitor 12/13/2016
BioDelivery (BDSI)'s Clonidine Topical Gel Fails to Meet Primary Efficacy Endpoint in Mid-Stage Study 12/13/2016
Centrexion Announces Highly Statistically Significant Topline Results From Phase 2b Study Of CNTX-4975 In Patients With Knee Osteoarthritis Pain 12/13/2016
SAGE Therapeutics (SAGE) Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Movement Disorders 12/13/2016
PHARNEXT Presents Positive Exploratory Phase 2 Data From PXT864 At The 9th Clinical Trials On Alzheimer’s Disease (CTAD) Conference In San Diego, United States 12/13/2016
3 Drugs Heading To The FDA Soon 12/12/2016
Axovant (AXON) Unveils New Data Analysis Showing Addition Of Intepirdine To Standard Therapy May Help People With Alzheimer's Disease Maintain Independence Longer 12/12/2016
Eisai Inc. (ESALF.PK) Presents Data On BACE Inhibitor Elenbecestat (E2609) At 9th Clinical Trials On Alzheimer's Disease (CTAD) Meeting 12/12/2016
Eiger Biopharma Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH) 12/12/2016
C3J Therapeutics Unveils Development Of Two New Product Formulations Of Lead Candidate C16G2 For Prevention Of Dental Caries 12/12/2016
Soligenix (SNGX) Announces SGX942 Receives Promising Innovative Medicine Designation From The UK Medicines And Healthcare Products Regulatory Agency 12/12/2016
RedHill Biopharma (RDHL) Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis 12/12/2016
Interim Results From Phase 1b/2 Study Evaluating The Combination Of Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) And Eisai Inc. (ESALF.PK)’s HALAVEN (Eribulin Mesylate) Injection In Metastatic Triple-Negative Breast Cancer Presented At 2016 SABCS 12/12/2016
Corcept Therapeutics Inc. (CORT) Announces Encouraging Results Of Phase 1/2 Trial Of Mifepristone Plus Eribulin In Triple-Negative Breast Cancer 12/12/2016
BioInvent (BOVNF) Terminates Current BI-505 Phase II Study 12/9/2016
3 Biotechs That Could Peak in 2017 12/9/2016
Probiodrug AG Release: Innovative Phase II Study Design Of Glutaminylcyclase Inhibitor PQ91 In Early Alzheimer’s Disease 12/8/2016
GTX Corp Reports Results From Ongoing Enobosarm Phase 2 Clinical Trial In ER+/AR+ Breast Cancer 12/8/2016
Puma Biotech (PBYI) Presents Results Of Biomarker Analysis Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer At The 2016 San Antonio Breast Cancer Symposium 12/8/2016
Puma Biotech (PBYI) Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2016 San Antonio Breast Cancer Symposium 12/8/2016
Helix Biopharma (TSX:HBP) Presents Topline L-DOS47 Results At The 17th IASCLC World Conference On Lung Cancer 12/8/2016
PellePharm, Inc Launches With Financing From BridgeBio Pharma To Develop Topical Therapy For Basal Cell Carcinomas And Gorlin Syndrome 12/8/2016
Soligenix (SNGX) Announces Positive Long-Term Follow-Up Results From Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 12/8/2016
Eli Lilly (LLY) Presents neoMONARCH Phase 2 Data On Abemaciclib In Early-Stage Breast Cancer 12/8/2016
Catalyst Pharma (CPRX) Provides Update On Its Clinical Trial For Patients With Congenital Myasthenic Syndromes 12/8/2016
Zynerba (ZYNE) To Host Clinical Research Day On December 15, 2016 To Discuss The Role Of ZYN002 CBD Gel In Multiple Diseases 12/8/2016
Tonix Pharma (TNXP) Presented New Clinical Results From Sub-Group Analysis Of Phase II Atease Study In Military-Related Posttraumatic Stress Disorder (PTSD) 12/8/2016
Puma Biotech (PBYI) Presents Interim Results Of Phase II CONTROL Trial Of PB272 In Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer At The 2016 San Antonio Breast Cancer Symposium 12/8/2016
Medivir (MVRBF) Release: MIV-711 Osteoarthritis Trial: Successful Third Independent Review Of Safety Data And Trial Continues Without Any Modifications 12/8/2016
EIP Pharma Announces Positive Results With Neflamapimod (VX-745) In Two Phase 2a Clinical Trials In Patients With Early Alzheimer's Disease 12/8/2016
Cascadian Therapeutics (ONTY) Amends HER2CLIMB Phase 2 Trial Of Tucatinib In Metastatic HER2-Positive Breast Cancer To Support Registration 12/8/2016
4 Massachusetts Biotechs Making Waves at American Society of Hematology 12/7/2016
Lycera Announces Initiation Of Phase 2 UPRISE Clinical Trial Of LYC-30937-EC For Patients With Moderate Psoriasis 12/7/2016
Viking Therapeutics (VKTX) Receives Orphan Drug Designation For VK0214 From The FDA For The Treatment Of X-Linked Adrenoleukodystrophy 12/7/2016
Arena (ARNA) Completes Enrollment In Ralinepag Phase 2 Clinical Trial For Pulmonary Arterial Hypertension (PAH) 12/7/2016
Origent And Cytokinetics (CYTK) Present Analyses Demonstrating Baseline Data Predict Measures Of Vital Capacity In Patients With ALS 12/7/2016
Progenics (PGNX) Announces First Patient Dosed In Phase II/III Clinical Trial Of PSMA-Targeted PET/CT Imaging Agent PyL 12/7/2016
Advaxis (ADXS) To Present Data At Imvacs-Immunization And Vaccine Summit On Use Of Detoxified Listeriolysin O (dtLLO) As An Effective Adjuvant In Vaccine Formulations 12/7/2016
Boehringer Ingelheim Release: Clinically Meaningful Data For Oral Nintedanib In Mesothelioma Presented At World Conference On Lung Cancer 12/7/2016
Neovacs Obtains FDA “Fast Track” Designation For IFNa Kinoid In Lupus (SLE) 12/7/2016
Struggling Ariad (ARIA) Finally Catches a Break, Shows Off Data From Brigatinib for Lung Cancer Trial 12/7/2016
With a New Name and Leader, Cascadian Therapeutics (ONTY) Rejigs Breast Cancer Study to Meet FDA's Standards 12/7/2016
FDA Approves Genentech (RHHBY)’s Avastin (Bevacizumab) Plus Chemotherapy For A Specific Type Of Advanced Ovarian Cancer 12/7/2016
Data From Omeros (OMER)’ OMS721 Phase 2 Clinical Trial In Patients With Stem Cell Transplant-Associated TMA To Be Presented At International Transplant Conference 12/7/2016
TRANSGENE (ENX:TNG), UC Davis To Conduct Phase II Trial Of The Combination Of TG4010 With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 12/7/2016
Celgene (CELG) Decides to Not Move Forward With Phase III Portion of tnAcity 12/7/2016
Ariad (ARIA)’s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival In ALTA Study 12/7/2016
Novartis AG (NVS)’ CAR-T Drug Sends 82% of Patients’ Blood Cancer into Remission, Eyes 2017 for Marketing 12/6/2016
Kite Pharma (KITE) Presents Results Of Multi-Center Pivotal ZUMA-1 Trial Of Axicabtagene Ciloleucel (KTE-C19) In Aggressive Non-Hodgkin Lymphoma As Late-Breaking Abstract At Annual Meeting Of American Society of Hematology 12/6/2016
SAGE Therapeutics (SAGE) Announces Expedited Development Plan For SAGE-547 In The Treatment Of Postpartum Depression Based On FDA Breakthrough Therapy Meeting 12/6/2016
AbbVie (ABBV) Release: New Phase 2 Data Show Nearly Half Of Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond To Treatment With Ibrutinib (IMBRUVICA) 12/6/2016
Janssen R&D Release: New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise In Relapsed/Refractory Marginal Zone Lymphoma (MZL), A Rare, Incurable Type Of Non-Hodgkin's Lymphoma 12/6/2016
Theravance Biopharma (TBPH) Receives FDA Fast Track Designation For Velusetrag (TD-5108) For Idiopathic And Diabetic Gastroparesis 12/6/2016
Mast Therapeutics (MSTX) Announces Initiation Of Patient Enrollment In Additional Phase 2 Study Of AIR001 For The Treatment Of Heart Failure With Preserved Ejection Fraction 12/6/2016
Achillion (ACHN) Release: Data Presented At American Society of Hematology Meeting Demonstrate Potential Advantages Of Factor D Inhibition For The Treatment Of Complement Alternative Pathway-Mediated Diseases 12/6/2016
Sangamo (SGMO) Presents Hemophilia A Program Data At The 2016 American Society of Hematology Meeting 12/6/2016